Mitomycin Facts Sheet (main)

This mini website about Mitomycin was prepared by a student of BioInformatics, the Open University.

alternate names: Mitomycin

Mitomycin is one of the older chemotherapy drugs, which has been around and in use for decades. It is an active medicine against many cancers. Mitomycin is a purple color powder, or liquid, and is given by intravenous route only. (http://www.tirgan.com/mitomycin.htm)

Mitomycin is chemotherapy that is given as a treatment for some types of cancer (http://www.cancerbacup.org.uk/info/mitomycin.htm)

COMMON TRADE NAME(S): Mutamycin®  (http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexALPro/Mitomycin.htm)

 

  1. Haskell CM, ed. Cancer treatment, 3rd ed. Philadelphia: WB Saunders Co, 1990.       
  2. Dorr RT, Fritz WL, eds. Cancer chemotherapy handbook. New York: Elsevier Science Publishing Co Inc, 1980:548-55.       
  3. Krogh CME, ed. Compendium of pharmaceuticals and specialties, 28th ed. Ottawa: Canadian Pharmaceutical Association, 1993:761-2.       
  4. Kastrup EK, et al, eds. Facts and comparisons: Loose-leaf information service. St. Louis: JB Lippincott Co, 1993:664.       
  5. Wiebe VJ, et al. Clinical pharmacokinetics of drugs used in the treatment of breast cancer. Clin Pharmacokin 1988;15:80-93.       
  6. Torti FM, et al. The biology and treatment of superficial bladder cancer. J Clin Onc 1984;2:505-31.       
  7. McEvoy GK, ed. American hospital formulary service: Drug information 1994. Bethesda: American Society of Hospital Pharmacists, 1994:669       
  8. Bennett WM. Guide to drug dosage in renal failure. Clin Pharmacokin 1988;15:326-54.       
  9. Pinedo HM, Chabner BA, eds. Cancer chemotherapy/7: The EORTC Cancer Chemotherapy Annual. New York: Elsevier Science Publishing Co Inc, 1985:83-90.       
  10. Crooke ST, et al. Phase I study of oral Mitomycin C. Cancer Treat Rep 1976;60:1633-6.       
  11. Vermeij J, den Hartigh J, Stuurman M, et al. Relationship between clinical parameters and pharmacokinetics of mitomycin. J Cancer Res Clin Oncol 1987;113:91-4.       
  12. Knoben JE, Anderson PO, eds. Handbook of clinical drug data, 6th ed. Hamilton: Drug Intelligence Publications Inc, 1988.       
  13. Dorr RT, Von Hoff DD. Cancer chemotherapy handbook, 2nd ed. Norwalk: Appleton & Lange, 1994:717-26.       
  14. Dorr RT. New findings in the pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin C. Semin Oncol 1988;15(No 3 Suppl 4):32-41.       
  15. Drugs of choice for cancer chemotherapy. Med Lett Drugs Ther 1993;35:43-50.       
  16. Buzdar AU, Legha SS, Tashima CK. Adriamycin and mitomycin C: Possible synergistic cardiotoxocity. Cancer Treat Rep 1978;62:1005-6.       
  17. Riggs CE. Antitumor antibiotics and related compounds. In: Perry MC, ed. The chemotherapy source book. Baltimore: Williams & Wilkins, 1992:337-40.       
  18. Leudke D, McLaughlin TT, Doughaday C, et al. Mitomycin C and vindesine associated pulmonary toxicity with variable clinical expression. Cancer 1985;55:542-5.       
  19. Bristol Laboratories of Canada. Mutamycin package insert. Belleville, Ontario.       
  20. Trissel LA. Handbook on injectable drugs, 7th ed. Bethesda: American Society of Hospital Pharmacists, 1992.       
  21. King JC. Guide to parenteral admixtures. St. Louis: KabiVitrum Inc, 1992.       
  22. Trissel LA, Tramonte SM, Grilley BJ. Visual compatability of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991;48:988-92.       
  23. Issell BF, et al. Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa. Cancer 1984;53:1025-28.       
  24. USP DI Volume I: Drug information for the health care professional, 14th ed. Rockville: United States Pharmacopeial Convention Inc, 1994:1934-7.       
  25. USP DI Volume II: Advice for the patient: Drug information in lay language, 14th ed. Rockville: United States Pharmacopeial Convention Inc, 1994:932-4.
  26. Au JL-S, Badalament RA, Wientjes MG, et al. Methods to Improve Efficacy of Intravesical Mitomycin C: Results of a Randomized Phase III Trial. JNCI Cancer Spectrum 2001;93(8):597-604.

 

 

Mitomycin is an Inhibitor of DNA synthesis and nuclear division. Antibacterial to gram positive, gram negative, and acid-fast bacilli.

The Mitomycin formula

Molecular Formula: C15H18N4O5
Molecular Weight: 334.3

 

Mitomycin biosynthesis (from http://www.cbs.umn.edu/asirc/biosynthetic_pathways/)

[top]

 




www.linkstoyou.com This page was done by a student of Bioinformatics, Open University Jerusalem Israel, in a homage to Fermentek and to Dr Berend.
 4mg  noneto biocompare formulae omd ToxicPlants DictCellBio MolBioDict ( test  position )
BioChemical Suppliers
A23187 Actinomycin Aflatoxin Anisomycin Aphidicolin Ascomycin
Bleomycin

Brefeldin

Cerulenin Chromomycin Geldanamycin Cyclopiazonic acid
Cytochalasin Forskolin Fumagillin Fumonisin Hypericin K252a
KT5823 Mitomycin Nigericin Ochratoxin Oligomycin Mycophenolic acid
Paclitaxel Patulin Paxilline Penitrem Puromycin Penicillic acid
Radicicol Rapamycin Staurosporine Sterigmatocystin Thapsigargin Tunicamycin
 Verruculogen  Wortmannin